Novel Curcumin-Resveratrol Solid Nanoparticles Synergistically Inhibit Proliferation of Melanoma Cells

Palliyage, Gayathri Heenatigala; Hussein, Noor; Mimlitz, Michael; Weeder, Catherine; Alnasser, Marya Hassan A; Singh, Somnath; Ekpenyong, Andrew; Tiwari, Amit K.; Chauhan, Harsh

doi:10.1007/s11095-021-03043-7

Cited by 30 publications

(29 citation statements)

References 75 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Over the years, research has been concentrated on the development of cancer nanomedicines, resulting in thousands of publications [9]. Different kinds of nanomedicines can be prepared, such as polymeric [7,[10][11][12][13][14][15] and dendrimeric [16,17] nanoparticles, solid lipid nanoparticles (SLNs) [18][19][20], liposomes [20], and nanomicelles [21].…”

Section: Introductionmentioning

confidence: 99%

Electrochemotherapy of Deep-Seated Tumors: State of Art and Perspectives as Possible “EPR Effect Enhancer” to Improve Cancer Nanomedicine Efficacy

Bonferoni

Rassu

Gavini

et al. 2021

Cancers

View full text Add to dashboard Cite

Surgical resection is the gold standard for the treatment of many kinds of tumor, but its success depends on the early diagnosis and the absence of metastases. However, many deep-seated tumors (liver, pancreas, for example) are often unresectable at the time of diagnosis. Chemotherapies and radiotherapies are a second line for cancer treatment. The “enhanced permeability and retention” (EPR) effect is believed to play a fundamental role in the passive uptake of drug-loaded nanocarriers, for example polymeric nanoparticles, in deep-seated tumors. However, criticisms of the EPR effect were recently raised, particularly in advanced human cancers: obstructed blood vessels and suppressed blood flow determine a heterogeneity of the EPR effect, with negative consequences on nanocarrier accumulation, retention, and intratumoral distribution. Therefore, to improve the nanomedicine uptake, there is a strong need for “EPR enhancers”. Electrochemotherapy represents an important tool for the treatment of deep-seated tumors, usually combined with the systemic (intravenous) administration of anticancer drugs, such as bleomycin or cisplatin. A possible new strategy, worthy of investigation, could be the use of this technique as an “EPR enhancer” of a target tumor, combined with the intratumoral administration of drug-loaded nanoparticles. This is a general overview of the rational basis for which EP could be envisaged as an “EPR enhancer” in nanomedicine.

show abstract

Section: Introductionmentioning

confidence: 99%

Electrochemotherapy of Deep-Seated Tumors: State of Art and Perspectives as Possible “EPR Effect Enhancer” to Improve Cancer Nanomedicine Efficacy

Bonferoni

Rassu

Gavini

et al. 2021

Cancers

View full text Add to dashboard Cite

show abstract

“…The ECIS is a noninvasive, robust device for electrically measuring a variety of cell characteristics, including morphology, proliferation, and migration [ 43 , 44 ]. The ECIS is a well-established, noninvasive mode of detecting changes in cell characteristics over extended periods, having been used in several studies, by others and by ourselves [ 45 , 46 , 47 ]. The primary focus of our work with the ECIS was an evaluation of possible pro- or antimetastatic effects of treatment.…”

Section: Methodsmentioning

confidence: 99%

Development of In Vitro Assays for Advancing Radioimmunotherapy against Brain Tumors

et al. 2022

Self Cite

View full text Add to dashboard Cite

Glioblastoma (GBM) is the most common primary brain tumor. Due to high resistance to treatment, local invasion, and a high risk of recurrence, GBM patient prognoses are often dismal, with median survival around 15 months. The current standard of care is threefold: surgery, radiation therapy, and chemotherapy with temozolomide (TMZ). However, patient survival has only marginally improved. Radioimmunotherapy (RIT) is a fourth modality under clinical trials and aims at combining immunotherapeutic agents with radiotherapy. Here, we develop in vitro assays for the rapid evaluation of RIT strategies. Using a standard cell irradiator and an Electric Cell Impedance Sensor, we quantify cell migration following the combination of radiotherapy and chemotherapy with TMZ and RIT with durvalumab, a PD-L1 immune checkpoint inhibitor. We measure cell survival using a cloud-based clonogenic assay. Irradiated T98G and U87 GBM cells migrate significantly (p < 0.05) more than untreated cells in the first 20–40 h post-treatment. Addition of TMZ increases migration rates for T98G at 20 Gy (p < 0.01). Neither TMZ nor durvalumab significantly change cell survival in 21 days post-treatment. Interestingly, durvalumab abolishes the enhanced migration effect, indicating possible potency against local invasion. These results provide parameters for the rapid supplementary evaluation of RIT against brain tumors.

show abstract

“…Palliyage et.al. [ 108 ] used the combination of curcumin with resveratrol and formulated solid lipid nanoparticles (diameter 180.2 ± 7.7 nm). The combination approach showed in vitro potential to stop metastasis in metastatic B16F10 cell lines based on electrical cell-substrate impedance sensing assay.…”

Section: Plant Product–based Transdermal Chemotherapeuticsmentioning

confidence: 99%

“…The combination approach showed in vitro potential to stop metastasis in metastatic B16F10 cell lines based on electrical cell-substrate impedance sensing assay. Further the combination showed synergistic effect in inhibiting the growth of SK-MEL-28 cells [ 108 ]. Overall, formulations such as nano-emulsion, liposomes, dendrimers, nano-capsules, etc., have been proven to enhance the solubility and thus permeability of resveratrol across the skin.…”

Section: Plant Product–based Transdermal Chemotherapeuticsmentioning

confidence: 99%

Transdermal Delivery of Chemotherapeutics: Strategies, Requirements, and Opportunities

et al. 2021

Self Cite

View full text Add to dashboard Cite

Chemotherapeutic drugs are primarily administered to cancer patients via oral or parenteral routes. The use of transdermal drug delivery could potentially be a better alternative to decrease the dose frequency and severity of adverse or toxic effects associated with oral or parenteral administration of chemotherapeutic drugs. The transdermal delivery of drugs has shown to be advantageous for the treatment of highly localized tumors in certain types of breast and skin cancers. In addition, the transdermal route can be used to deliver low-dose chemotherapeutics in a sustained manner. The transdermal route can also be utilized for vaccine design in cancer management, for example, vaccines against cervical cancer. However, the design of transdermal formulations may be challenging in terms of the conjugation chemistry of the molecules and the sustained and reproducible delivery of therapeutically efficacious doses. In this review, we discuss the nano-carrier systems, such as nanoparticles, liposomes, etc., used in recent literature to deliver chemotherapeutic agents. The advantages of transdermal route over oral and parenteral routes for popular chemotherapeutic drugs are summarized. Furthermore, we also discuss a possible in silico approach, Formulating for Efficacy™, to design transdermal formulations that would probably be economical, robust, and more efficacious.

show abstract

Novel Curcumin-Resveratrol Solid Nanoparticles Synergistically Inhibit Proliferation of Melanoma Cells

Cited by 30 publications

References 75 publications

Electrochemotherapy of Deep-Seated Tumors: State of Art and Perspectives as Possible “EPR Effect Enhancer” to Improve Cancer Nanomedicine Efficacy

Electrochemotherapy of Deep-Seated Tumors: State of Art and Perspectives as Possible “EPR Effect Enhancer” to Improve Cancer Nanomedicine Efficacy

Development of In Vitro Assays for Advancing Radioimmunotherapy against Brain Tumors

Transdermal Delivery of Chemotherapeutics: Strategies, Requirements, and Opportunities

Contact Info

Product

Resources

About